Sign in or create an account to add this stock to your watchlist.
About Cytokinetics (NASDAQ:CYTK)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CYTK
CUSIPN/A
Phone650-624-3000
Debt
Debt-to-Equity Ratio0.32
Current Ratio7.07
Quick Ratio7.07
Price-To-Earnings
Trailing P/E Ratio-3.38
Forward P/E Ratio-4.20
P/E GrowthN/A
Sales & Book Value
Annual Sales$13.37 million
Price / Sales35.27
Cash FlowN/A
Price / CashN/A
Book Value$1.84 per share
Price / Book4.73
Profitability
EPS (Most Recent Fiscal Year)($2.59)
Net Income$-127,790,000.00
Net Margins-172.27%
Return on Equity-99.50%
Return on Assets-42.59%
Miscellaneous
Employees137
Outstanding Shares54,200,000
Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions
What is Cytokinetics' stock symbol?
Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."
How were Cytokinetics' earnings last quarter?
Cytokinetics (NASDAQ:CYTK) announced its quarterly earnings results on Thursday, April, 26th. The biopharmaceutical company reported ($0.56) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.50) by $0.06. The biopharmaceutical company had revenue of $5.27 million for the quarter, compared to analyst estimates of $5.50 million. Cytokinetics had a negative return on equity of 99.50% and a negative net margin of 172.27%. View Cytokinetics' Earnings History.
When is Cytokinetics' next earnings date?
What price target have analysts set for CYTK?
8 brokers have issued twelve-month price objectives for Cytokinetics' shares. Their forecasts range from $10.00 to $24.00. On average, they anticipate Cytokinetics' share price to reach $15.75 in the next year. View Analyst Ratings for Cytokinetics.
What are Wall Street analysts saying about Cytokinetics stock?
Here are some recent quotes from research analysts about Cytokinetics stock:
- 1. Cantor Fitzgerald analysts commented, "Robert Califf, M.D. has joined CYTK’s Board of Directors (BoD), adding his expertise in cardiovascular and regulatory domains, we believe." (2/12/2018)
- 2. According to Zacks Investment Research, "Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or deteriorating. With an unmatched understanding of muscle biology and mechanics of muscle performance, the company is developing small molecule drug candidates engineered to increase muscle function and contractility. Cytokinetics' lead drug candidate is tirasemtiv, a fast skeletal muscle activator, for the potential treatment of ALS. Tirasemtiv has been granted orphan drug designation and fast track status by the FDA and orphan medicinal product designation by the EMA. Cytokinetics is collaborating with Amgen Inc. to develop omecamtiv mecarbil, a novel cardiac muscle activator, for the potential treatment of heart failure, and with Astellas Pharma Inc. to develop CK-2127107, a fast skeletal muscle activator, for the potential treatment of spinal muscular atrophy. " (8/17/2017)
- 3. Cowen Inc analysts commented, "CYTK reported a Q2 loss of $29.1MM and ended the quarter with $332MM in cash." (8/4/2017)
Who are some of Cytokinetics' key competitors?
Some companies that are related to Cytokinetics include Phibro Animal Health (PAHC), MyoKardia (MYOK), Prestige Brands (PBH), Madrigal Pharmaceuticals (MDGL), Akorn (AKRX), Motif (MTFB), G1 Therapeutics (GTHX), Cambrex (CBM), ARMO BioSciences (ARMO), Innoviva (INVA), Zogenix (ZGNX), PTC Therapeutics (PTCT), Pacira Pharmaceuticals (PCRX), ImmunoGen (IMGN) and Impax Laboratories (IPXL).
Who are Cytokinetics' key executives?
Cytokinetics' management team includes the folowing people:
- Mr. Robert I. Blum, CEO, Pres & Director (Age 54)
- Mr. Ching W. Jaw, Sr. VP & CFO (Age 55)
- Dr. Andrew A. Wolff, Sr. VP & Chief Medical Officer (Age 63)
- Dr. Fady Ibraham Malik, Exec. VP of R&D (Age 54)
- Dr. Bradley Paul Morgan, Sr. VP of Research & Non-Clinical Devel. (Age 58)
Has Cytokinetics been receiving favorable news coverage?
Media stories about CYTK stock have trended somewhat positive this week, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cytokinetics earned a media sentiment score of 0.23 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 45.29 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Cytokinetics' major shareholders?
Cytokinetics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.44%), Wasatch Advisors Inc. (3.26%), Pinnacle Associates Ltd. (1.64%), Citigroup Inc. (1.43%), Principal Financial Group Inc. (0.73%) and Principal Financial Group Inc. (0.74%). Company insiders that own Cytokinetics stock include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Institutional Ownership Trends for Cytokinetics.
Which major investors are selling Cytokinetics stock?
CYTK stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Dimensional Fund Advisors LP, Schwab Charles Investment Management Inc. and American International Group Inc.. Company insiders that have sold Cytokinetics company stock in the last year include Bradley Paul Morgan, Caryn Gordon Mcdowell, Fady Ibraham Malik, Robert I Blum and Santo J Costa. View Insider Buying and Selling for Cytokinetics.
Which major investors are buying Cytokinetics stock?
CYTK stock was bought by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Millennium Management LLC, Employees Retirement System of Texas, A.R.T. Advisors LLC, UBS Group AG, JPMorgan Chase & Co., BlackRock Inc. and DRW Securities LLC. View Insider Buying and Selling for Cytokinetics.
How do I buy shares of Cytokinetics?
Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytokinetics' stock price today?
One share of CYTK stock can currently be purchased for approximately $8.75.
How big of a company is Cytokinetics?
Cytokinetics has a market capitalization of $466.10 million and generates $13.37 million in revenue each year. The biopharmaceutical company earns $-127,790,000.00 in net income (profit) each year or ($2.59) on an earnings per share basis. Cytokinetics employs 137 workers across the globe.
How can I contact Cytokinetics?
Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]
MarketBeat Community Rating for Cytokinetics (CYTK)
MarketBeat's community ratings are surveys of what our community members think about Cytokinetics and other stocks. Vote "Outperform" if you believe CYTK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTK will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cytokinetics (NASDAQ:CYTK) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Cytokinetics in the last 12 months. Their average twelve-month price target is $15.75, suggesting that the stock has a possible upside of 81.03%. The high price target for CYTK is $24.00 and the low price target for CYTK is $10.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.88 | 2.88 | 2.89 | 2.90 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $15.75 | $15.75 | $16.7778 | $17.90 |
| Price Target Upside: | 81.03% upside | 118.75% upside | 116.49% upside | 116.97% upside |
Cytokinetics (NASDAQ:CYTK) Consensus Price Target History
Cytokinetics (NASDAQ:CYTK) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Cytokinetics (NASDAQ:CYTK) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cytokinetics (NASDAQ CYTK) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 68.07%
Cytokinetics (NASDAQ CYTK) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/4/2018 | Robert I Blum | CEO | Sell | 4,000 | $8.38 | $33,520.00 | 183,722 |  |
| 4/5/2018 | Robert I Blum | CEO | Sell | 4,000 | $7.52 | $30,080.00 | 182,701 | |
| 1/16/2018 | Caryn Gordon Mcdowell | Insider | Sell | 2,709 | $9.00 | $24,381.00 | 15,077 | |
| 11/2/2017 | Caryn Gordon Mcdowell | Insider | Sell | 4,260 | $12.94 | $55,124.40 | 17,982 | |
| 11/1/2017 | Fady Ibraham Malik | EVP | Sell | 7,321 | $13.39 | $98,028.19 | 47,540 | |
| 11/1/2017 | Robert I Blum | CEO | Sell | 5,000 | $13.51 | $67,550.00 | 70,180 | |
| 10/6/2017 | Caryn Gordon Mcdowell | Insider | Sell | 13,181 | $15.49 | $204,173.69 | | |
| 10/2/2017 | Robert I Blum | CEO | Sell | 5,000 | $14.59 | $72,950.00 | | |
| 9/6/2017 | Caryn Gordon Mcdowell | Insider | Sell | 10,131 | $14.60 | $147,912.60 | 19,801 | |
| 9/1/2017 | Robert I Blum | CEO | Sell | 5,000 | $14.71 | $73,550.00 | 79,785 | |
| 8/31/2017 | Bradley Paul Morgan | SVP | Sell | 118,330 | $15.00 | $1,774,950.00 | 63,107 | |
| 8/31/2017 | Santo J Costa | Director | Sell | 5,000 | $15.00 | $75,000.00 | 5,000 | |
| 8/29/2017 | Santo J Costa | Director | Sell | 5,000 | $14.00 | $70,000.00 | 5,000 | |
| 8/8/2017 | Caryn Gordon Mcdowell | Insider | Sell | 11,348 | $12.47 | $141,509.56 | 21,570 | |
| 8/1/2017 | Robert I Blum | CEO | Sell | 5,000 | $13.79 | $68,950.00 | 84,785 | |
| 7/3/2017 | Robert I Blum | CEO | Sell | 5,000 | $12.14 | $60,700.00 | 88,385 | |
| 6/1/2017 | Robert I Blum | CEO | Sell | 5,000 | $13.62 | $68,100.00 | 94,785 | |
| 12/29/2016 | Fady Ibraham Malik | EVP | Sell | 5,633 | $12.36 | $69,623.88 | 3,361 | |
| 8/31/2015 | L Patrick Gage | Director | Buy | 1,000 | $6.95 | $6,950.00 | 30,000 | |
| 8/20/2015 | L Patrick Gage | Director | Buy | 10,000 | $6.55 | $65,500.00 | 30,000 | |
| 5/6/2015 | L Patrick Gage | Director | Buy | 10,000 | $5.71 | $57,100.00 | | |
| 3/11/2015 | Andrew A Wolff | CMO | Sell | 21,875 | $7.80 | $170,625.00 | | |
| 12/30/2014 | Fady Ibraham Malik | SVP | Sell | 21,630 | $6.73 | $145,569.90 | | |
| 5/9/2014 | L Patrick Gage | Director | Buy | 10,850 | $4.09 | $44,376.50 | 10,000 | |
| 2/25/2014 | Eastern Capital Ltd | major shareholder | Buy | 500,000 | $8.00 | $4,000,000.00 | 2,883,845 | |
(Data available from 1/1/2013 forward)
Cytokinetics (NASDAQ CYTK) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Cytokinetics and Cure SMA Renew and Expand Partnership to Advance Education and Awareness of SMA
finance.yahoo.com - May 17 at 3:10 PM |
 | Zacks: Brokerages Expect Cytokinetics (CYTK) Will Post Quarterly Sales of $5.57 Million
www.americanbankingnews.com - May 12 at 2:06 AM |
| Cytokinetics to Hold Annual Meeting of Stockholders
finance.yahoo.com - May 11 at 5:18 AM |
| Zacks: Brokerages Anticipate Cytokinetics (CYTK) to Announce -$0.51 Earnings Per Share
www.americanbankingnews.com - May 10 at 7:19 PM |
| Cytokinetics (CYTK) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 7 at 1:49 PM |
| Robert I. Blum Sells 4,000 Shares of Cytokinetics (CYTK) Stock
www.americanbankingnews.com - May 4 at 8:15 PM |
| Brokers Issue Forecasts for Cytokinetics' FY2018 Earnings (CYTK)
www.americanbankingnews.com - May 2 at 9:42 AM |
| Cytokinetics (CYTK) Upgraded to Hold at BidaskClub
www.americanbankingnews.com - April 28 at 8:34 AM |
| Cytokinetics (CYTK) Lifted to Hold at ValuEngine
www.americanbankingnews.com - April 27 at 10:52 PM |
| Cytokinetics (CYTK) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - April 27 at 4:12 PM |
| Edited Transcript of CYTK earnings conference call or presentation 26-Apr-18 8:30pm GMT
finance.yahoo.com - April 27 at 3:02 PM |
| Cytokinetics (CYTK) Given a $20.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 27 at 12:34 PM |
 | BRIEF-Cytokinetics Reports Q1 Loss Per Share Of $0.56
www.reuters.com - April 27 at 5:11 AM |
 | Cytokinetics' (CYTK) CEO Robert Blum on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - April 27 at 5:11 AM |
| Cytokinetics, Inc. Reports First Quarter 2018 Financial Results
finance.yahoo.com - April 27 at 5:11 AM |
| Cytokinetics: 1Q Earnings Snapshot
finance.yahoo.com - April 27 at 5:11 AM |
| Is Cytokinetics Incorporated (NASDAQ:CYTK) Worth $7.25 Based On Intrinsic Value?
finance.yahoo.com - April 26 at 3:02 PM |
 | Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal ...
globenewswire.com - April 24 at 3:10 PM |
| Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference
finance.yahoo.com - April 24 at 3:10 PM |
| Cantor Fitzgerald Analysts Give Cytokinetics (CYTK) a $10.00 Price Target
www.americanbankingnews.com - April 24 at 10:28 AM |
| Cytokinetics (CYTK) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 18 at 3:44 AM |
| Cytokinetics (CYTK) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 16 at 10:54 AM |
| Cytokinetics (CYTK) Given a $26.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 13 at 7:15 PM |
| Cytokinetics to Announce First Quarter Results on April 26, 2018
globenewswire.com - April 13 at 5:03 AM |
| Cytokinetics to Announce First Quarter Results on April 26, 2018
finance.yahoo.com - April 13 at 5:03 AM |
| Cytokinetics (CYTK) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 12 at 1:41 PM |
| Insider Selling: Cytokinetics, Inc. (CYTK) CEO Sells 4,000 Shares of Stock
www.americanbankingnews.com - April 6 at 7:33 PM |
| Cytokinetics (CYTK) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 5 at 2:09 PM |
| Cytokinetics (CYTK) Downgraded by TheStreet
www.americanbankingnews.com - April 2 at 9:42 PM |
| Edited Transcript of CYTK earnings conference call or presentation 15-Feb-18 9:30pm GMT
finance.yahoo.com - April 1 at 5:00 AM |
| Cytokinetics (CYTK) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - March 29 at 11:18 PM |
| Cytokinetics (CYTK) Rating Increased to Sell at BidaskClub
www.americanbankingnews.com - March 24 at 1:11 PM |
| Cytokinetics, Inc. (CYTK) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 18 at 1:48 PM |
| Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
finance.yahoo.com - February 28 at 3:13 PM |
| Cytokinetics (CYTK) PT Raised to $18.00
www.americanbankingnews.com - February 21 at 5:30 PM |
| Cytokinetics, Inc. (CYTK) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 21 at 2:31 PM |
| Cytokinetics (CYTK) Earns Buy Rating from Cowen
www.americanbankingnews.com - February 20 at 8:26 PM |
| Cytokinetics Sees Unusually Large Options Volume (CYTK)
www.americanbankingnews.com - February 20 at 6:56 AM |
| Cytokinetics (CYTK) Announces Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - February 16 at 11:40 AM |
| Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - February 16 at 5:10 AM |
| Cytokinetics reports 4Q loss
finance.yahoo.com - February 16 at 5:10 AM |
| Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results
finance.yahoo.com - February 16 at 5:10 AM |
| Cytokinetics, Inc. (CYTK) Expected to Post Quarterly Sales of $4.83 Million
www.americanbankingnews.com - February 16 at 3:46 AM |
 | Cytokinetics Earnings Outlook - Benzinga
www.benzinga.com - February 15 at 3:10 PM |
| Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - February 15 at 5:10 AM |
| Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 15 at 5:10 AM |
| Analysts Expect Cytokinetics, Inc. (CYTK) Will Announce Earnings of -$0.71 Per Share
www.americanbankingnews.com - February 14 at 5:16 PM |
| Cytokinetics Names Robert Califf, M.D., to Board of Directors ... - GlobeNewswire (press release)
www.globenewswire.com - February 14 at 3:09 PM |
 | Cytokinetics (CYTK) Names Robert Califf to Board of Directors
www.streetinsider.com - February 13 at 3:07 PM |
| Cytokinetics' (CYTK) Hold Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - February 12 at 4:18 PM |
Cytokinetics (NASDAQ:CYTK) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cytokinetics (NASDAQ:CYTK) Income Statement, Balance Sheet and Cash Flow Statement
Cytokinetics (NASDAQ CYTK) Stock Chart for Thursday, May, 24, 2018
Loading chart…
